实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2014年
8期
987-989
,共3页
乳腺癌%腔镜%保乳术%新辅助化疗%表柔比星
乳腺癌%腔鏡%保乳術%新輔助化療%錶柔比星
유선암%강경%보유술%신보조화료%표유비성
Breast cancer%Mastoscopy treatment%Breast-conserving surgery%Neoadjuvant chemotherapy%Epirubicin
目的：探讨腔镜辅助下乳腺癌保乳术结合表柔比星新辅助化疗治疗乳腺癌的临床疗效。方法选择96例Ⅰ～Ⅱ期乳腺癌患者为研究对象，其中行腔镜辅助下乳腺癌保乳术治疗者（腔镜组）50例，传统保乳术（传统组）治疗者46例，所有患者均给予表柔比星联合多西他赛（ TE）新辅助化疗方案。比较2组5年生存率、复发率、手术效果及美容效果，记录化疗不良反应。结果腔镜组与传统组5年生存率分别为94．0％和95．7％，复发率为6．0％和6．5％（ P＞0．05）；2组清扫淋巴结数无显著差异（P＞0．05）；腔镜组乳房美容优良率、平均引流量及拔管时间优于传统组（P＜0．05）；全组脱发、中性粒细胞下降及消化道反应不良反应发生率分别为89．6％、66．7％和41．7％，经对症处置后患者均完成治疗。结论腔镜辅助下乳腺癌保乳术结合表柔比星新辅助化疗临床疗效理想，对机体损伤小，药物不良反应可耐受。
目的：探討腔鏡輔助下乳腺癌保乳術結閤錶柔比星新輔助化療治療乳腺癌的臨床療效。方法選擇96例Ⅰ～Ⅱ期乳腺癌患者為研究對象，其中行腔鏡輔助下乳腺癌保乳術治療者（腔鏡組）50例，傳統保乳術（傳統組）治療者46例，所有患者均給予錶柔比星聯閤多西他賽（ TE）新輔助化療方案。比較2組5年生存率、複髮率、手術效果及美容效果，記錄化療不良反應。結果腔鏡組與傳統組5年生存率分彆為94．0％和95．7％，複髮率為6．0％和6．5％（ P＞0．05）；2組清掃淋巴結數無顯著差異（P＞0．05）；腔鏡組乳房美容優良率、平均引流量及拔管時間優于傳統組（P＜0．05）；全組脫髮、中性粒細胞下降及消化道反應不良反應髮生率分彆為89．6％、66．7％和41．7％，經對癥處置後患者均完成治療。結論腔鏡輔助下乳腺癌保乳術結閤錶柔比星新輔助化療臨床療效理想，對機體損傷小，藥物不良反應可耐受。
목적：탐토강경보조하유선암보유술결합표유비성신보조화료치료유선암적림상료효。방법선택96례Ⅰ～Ⅱ기유선암환자위연구대상，기중행강경보조하유선암보유술치료자（강경조）50례，전통보유술（전통조）치료자46례，소유환자균급여표유비성연합다서타새（ TE）신보조화료방안。비교2조5년생존솔、복발솔、수술효과급미용효과，기록화료불량반응。결과강경조여전통조5년생존솔분별위94．0％화95．7％，복발솔위6．0％화6．5％（ P＞0．05）；2조청소림파결수무현저차이（P＞0．05）；강경조유방미용우량솔、평균인류량급발관시간우우전통조（P＜0．05）；전조탈발、중성립세포하강급소화도반응불량반응발생솔분별위89．6％、66．7％화41．7％，경대증처치후환자균완성치료。결론강경보조하유선암보유술결합표유비성신보조화료림상료효이상，대궤체손상소，약물불량반응가내수。
Objective To explore the effect of breast-conserving surgery assisted by mastoscopy combined with epirubi-cin neoadjuvant chemotherapy for breast cancer .Methods 96 cases of stage Ⅰ~Ⅱbreast cancer patients were selected as re-search subjects ,including 50 cases of endoscopic group who underwent breast-conserving surgery assisted by mastoscopy and 46 cases of traditional group who received traditional breast-conserving surgery .All the patients were given epirubicin and docetaxel (TE scheme).5 year survival rate,recurrence rate,operation effect and cosmetic effects were compared between the 2 groups.The adverse reactions of chemotherapy were recorded .Results 5 year survival rates were 94.0%and 95.7%,recurrence rates were 6.0%and 6.5%in endoscopic group and traditional group respectively ( P>0.05);There were no significant difference in num-ber of lymph node dissection between the 2 groups (P>0.05);Mean drainage and extubation time in endoscopic group was supe-rior to traditional group (P<0.05);Alopecia,neutropenia and the reaction of digestive tract were 89.6%,66.7%and 41.7%;All the patients completed the treatment after symptomatic treatment .Conclusion Breast-conserving surgery assisted by masto-scopy combined with epirubicin neoadjuvant chemotherapy for breast cancer has ideal curative effect with less injure for body and tolerable adverse reactions .
